FGFR2 and infantile convulsions and choreoathetosis: Recent advances in molecular profiling of ICCA have enabled the development of targeted therapeutic approaches, particularly agents directed against fibroblast growth factor receptor 2 (FGFR2) fusions and isocitrate dehydrogenase 1 (IDH1) mutations, which have shown encouraging outcomes in selected patient subsets 5-7.